Eterna Therapeutics Presents Development Of Beta 2 Microglobulin-Knockout iMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features That May Further Augment The Therapeutic Potential Of MSCs In Inflammatory Diseases At The ASGCT Annual Meeting

• The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells
• The presentation is on Saturday, May 11th, 2024

CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene + Cell Therapy, taking place in Baltimore, Maryland.